Contact:
4008465777
-
About Us
News & Events
-
04-22
For ten consecutive years | Tonghua Dongbao publishes 2022 CSR Report
On April 20, Tonghua Dongbao Pharmaceutical Co., Ltd. (stock code: 600867, hereinafter referred to as "Tonghua Dongbao" or the "Company") released its 2022 Corporate Social Responsibility (CSR) Report...
-
04-21
Tonghua Dongbao: Product sales show steady growth in 2022, securing the largest human insulin market share in China
Tonghua Dongbao Pharmaceutical Co., Ltd. (stock code: 600867, hereinafter referred to as "Tonghua Dongbao" or the "Company") released its 2022 Annual Report on April 20. In 2022, the Company recorded ...
-
02-08
Tonghua Dongbao: First subject enrolled in Phase II clinical trial on novel URAT1 inhibitor (THDBH130 Tablets) for gout
Recently, Dongbao Zixing (Hangzhou) Biopharmaceutical Co., Ltd., a wholly owned subsidiary of Tonghua Dongbao Pharmaceutical Co., Ltd. ("the Company") has enrolled the first subject in the Phase II cl...
-
02-07
Tonghua Dongbao 2022 results: Insulin sales continue to grow
On February 6, 2023, Tonghua Dongbao Pharmaceutical Co., Ltd. (stock code: 600867, hereinafter referred to as "Tonghua Dongbao" or the "Company") released its financial results for 2022. Revenue is es...
-
02-02
Tonghua Dongbao's application of human insulin injection accepted by EMA
On February 1, 2023, Tonghua Dongbao Pharmaceutical Co., Ltd. ("the Company" or "Tonghua Dongbao") and Rechon Life Science AB ("Rechon") announced that the marketing authorization application (MAA) fo...
-
01-18
Tonghua Dongbao's Phase I clinical trial on its URAT1 inhibitor (THDBH130 Tablets) meets primary endpoint
Dongbao Zixing (Hangzhou) Biopharmaceutical Co., Ltd., a wholly owned subsidiary of Tonghua Dongbao Pharmaceutical Co., Ltd. ("the Company" or "Tonghua Dongbao"), recently completed a Phase I pivotal ...